Lilly Pharmaceuticals announced on March 8th local time that the US Food and Drug Administration (FDA) has notified the company to further understand and evaluate the safety and efficacy of its new Alzheimer's disease drug donanemab, and is expected to hold an external expert meeting to discuss the phase 3 trial of the drug. Lilly stated that the FDA has not yet determined the date of the advisory committee meeting, therefore the expected approval time for donanemab will be postponed to after the first quarter of 2024. Affected by this news, Lilly's stock price closed down 2.3%.